Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TAVO412 a Two-stage, Open-label, Phase I Study in Patients with Advanced/metastatic Solid Tumors Who Have Received Standard of Care

NCT06761651 is registered in ClinicalTrials.gov with Tavotek Biotherapeutics as lead sponsor.

NCT NCT06761651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06761651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TAVO412 a Two-stage, Open-label, Phase I Study in Patients with Advanced/metastatic Solid Tumors Who Have Received Standard of Care
Lead sponsor
Tavotek Biotherapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
December 20, 2023
Completion date
October 15, 2026
Enrollment
50 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cancer